REFERENCES

1. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989;84:353-5.

2. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17-21.

3. Ong AA, Sherris DA. Neurotoxins. Facial Plast Surg 2019;35:230-8.

4. American Society of Plastic Surgeons News Release. Plastic Surgery Statistics Report. Available from: https://www.plasticsurgery.org/news/plastic-surgery-statistics. [Last accessed on 10 Nov 2020].

5. Berwick S, Humble Á. Older women’s negative psychological and physical experiences with injectable cosmetic treatments to the face. J Women Aging 2017;29:51-62.

6. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43:249-59.

7. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.

8. Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 2012;67:226-32.

9. Hexsel D, Soirefmann M, Porto MD, Siega C, Schilling-Souza J, Rodrigues TC. Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study. Dermatol Surg 2015;41 Suppl 1:S110-8.

10. Cohn JE, Greco TM. Advanced techniques for the use of Neurotoxins in non-surgical facial rejuvenation. Aesthetic Plast Surg 2020;44:1788-99.

11. Rohrich RJ, Ghavami A, Crosby MA. The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations. Plast Reconstr Surg 2007;120:41S-54.

12. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089-98.

13. Beer JI, Sieber DA, Scheuer JF 3rd, Greco TM. Three-dimensional facial anatomy: structure and function as it relates to injectable neuromodulators and soft tissue fillers. Plast Reconstr Surg Glob Open 2016;4:e1175.

14. Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatol Online J 2005;11:9.

15. Fabi SG, Sundaram H, Guiha I, Goldman MP. A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides. J Drugs Dermatol 2013;12:932-7.

16. Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003;29:468-76.

17. Loos BM, Maas CS. Relevant anatomy for botulinum toxin facial rejuvenation. Facial Plast Surg Clin North Am 2003;11:439-43.

18. Suber JS, Dinh TP, Prince MD, Smith PD. OnabotulinumtoxinA for the treatment of a “gummy smile”. Aesthet Surg J 2014;34:432-7.

19. Sucupira E, Abramovitz A. A simplified method for smile enhancement: botulinum toxin injection for gummy smile. Plast Reconstr Surg 2012;130:726-8.

20. Choi YJ, Kim JS, Gil YC, et al. Anatomical considerations regarding the location and boundary of the depressor anguli oris muscle with reference to botulinum toxin injection. Plast Reconstr Surg 2014;134:917-21.

21. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg 2010;125:1693-705.

22. Matarasso A, Matarasso SL. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 2003;112:138S-40.

23. Filipo R, Spahiu I, Covelli E, Nicastri M, Bertoli GA. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope 2012;122:266-70.

24. King M. Management of Ptosis. J Clin Aesthet Dermatol 2016;9:E1-4.

25. Olson JJ. Balanced botox chemodenervation of the upper face: symmetry in motion. Semin Plast Surg 2007;21:47-53.

26. Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006;81:1023-8.

27. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol 2007;25:9-18.

28. Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the pathophysiology of hypertrophic scars and keloids: How do they differ? Adv Skin Wound Care 2018;31:582-95.

29. Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol 2019;18:10-5.

30. Xiao Z, Qu G. Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules 2012;17:2169-77.

31. Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to Botulinum toxin A: a comprehensive literature review. Dermatol Surg 2018;44:149-57.

32. Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician 2014;90:168-75.

33. Batniji RK, Falk AN. Update on botulinum toxin use in facial plastic and head and neck surgery. Curr Opin Otolaryngol Head Neck Surg 2004;12:317-22.

34. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010;25:2211-8.